|
Feasibility and benefit of molecularly-informed enrollment into early phase trials for patients with recurrent gliomas. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca; Lilly; Pfizer; Roche |
Travel, Accommodations, Expenses - Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Amgen |
Travel, Accommodations, Expenses - Amgen; SERVIER |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - AstraZeneca |
Honoraria - AstraZeneca; Bristol-Myers Squibb; Pfizer; Pierre Fabre; Roche; Sanofi |
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Pfizer; Pierre Fabre; Roche; Sanofi |
|
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Proacta |
Research Funding - CarThera (Inst) |
Travel, Accommodations, Expenses - CarThera; Proacta |
|
|
Other Relationship - Amgen; Astellas Oncology; AstraZeneca; Bayer; Celgene; Genentech; Ipsen; Janssen; Lilly; Novartis; Orion; Pfizer; Roche; Sanofi |
|
|
No Relationships to Disclose |